玻璃体内抗血管内皮生长因子注射治疗渗出性视网膜动脉大动脉瘤
这项回顾性多中心干预研究评估了抗血管内皮生长因子(anti-VEGF)治疗症状性视网膜动脉大动脉瘤(RAM)的效果,32眼平均接受2.7次注射、平均随访16.6个月,首次注射后1、2、3个月中心黄斑厚度分别下降131、180、211 μm(P < 0.001),最佳矫正视力在2、3个月分别提高0.47和0.38个Early Treatment Diabetic Retinopathy Study行(P = 0.005),作者结论为症状性RAM可经anti-VEGF注射成功治疗并减轻黄斑水肿。
要点
- 32眼症状性RAM接受anti-VEGF注射,平均2.7次,平均随访16.6个月。
- 首次注射后1、2、3个月中心黄斑厚度分别下降131、180、211 μm(P < 0.001)。
- 最佳矫正视力在2、3个月分别提高0.47和0.38个ETDRS行(P = 0.005)。
核心结论
- 症状性视网膜动脉大动脉瘤可经抗血管内皮生长因子注射成功治疗,并导致黄斑水肿减轻。
研究设计与样本
- 回顾性多中心干预研究,纳入症状性视网膜动脉大动脉瘤患眼,评估anti-VEGF治疗效果。
- 共32眼(32例患者),平均接受2.7次注射,平均随访16.6个月。
- 中心黄斑厚度以μm计、最佳矫正视力以logMar计,并与RAM大小及距黄斑距离进行相关分析。
- 统计分析采用配对比较和Pearson相关。
主要发现
- 初始最佳矫正视力与RAM大小及距黄斑距离相关(P = 0.02)。
- 首次注射后1、2、3个月中心黄斑厚度分别下降131、180、211 μm(P < 0.001)。
- 最佳矫正视力在2、3个月分别提高0.47和0.38个Early Treatment Diabetic Retinopathy Study行(P = 0.005)。
- anti-VEGF反应与RAM大小(P = 0.04)及距黄斑距离(P = 0.009)相关。
临床怎么用
- 原文结论为症状性RAM可经anti-VEGF注射成功治疗,并导致黄斑水肿减轻。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There is no established therapy for exudative-hemorrhagic complications in primary retinal arteriolar macroaneurysm (RAM). METHODS: Retrospective multicenter interventional study of anti-vascular endothelial growth factor in symptomatic RAMs. Central macular thickness in μm and best-corrected visual acuity in logMar were correlated with the RAM size and distance to the macula. Statistical analyses were performed using paired comparisons and Pearson correlation. RESULTS: Thirty-two eyes (32 patients) were treated with a mean of 2.7 injections over a mean follow-up of 16.6 months. Initial best-corrected visual acuity correlated with the RAM size and distance to the macula (P = 0.02). Central macular thickness decreased by 131,180, and 211 μm at 1, 2, and 3 months after the first injection (P < 0.001). Best-corrected visual acuity improved by 0.47 and 0.38 Early Treatment Diabetic Retinopathy Study lines at 2 and 3 months (P = 0.005). Anti-vascular endothelial growth factor response correlated with the RAM size (P = 0.04) and the distance to the macula (P = 0.009). CONCLUSION: Symptomatic RAMs can be treated successfully with anti-vascular endothelial growth factor injections, leading to a decrease in macular edema.
引用
- Mansour AM, Foster RE, Gallego-Pinazo R, et al. INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS FOR EXUDATIVE RETINAL ARTERIAL MACROANEURYSMS. Retina. 2019. PMID: 29505440. doi:10.1097/IAE.0000000000002131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。